Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer

Gassner L, Wild C, Hofer V
Record ID 32018002668
Authors' objectives: This systematic review evaluates whether percutaneous hepatic perfusion is more effective and safer compared to best available care for patients with liver cancer.
Authors' results and conclusions: One randomised controlled trial and one case series were included. Percutaneous hepatic perfusion might be more effective than best available care in terms of overall progression-free and hepatic progression-free survival. No evidence was identified regarding the quality of life, and overall survival did not improve due to percutaneous hepatic perfusion. Serious, well-recognised complications regarding safety were shown. Three of four deaths were attributed to percutaneous hepatic perfusion. Procedure-related complications were observed in the majority of patients, and many discontinued percutaneous hepatic perfusion. The available evidence is insufficient and with too limited internal and external validity to demonstrate clinical benefits of percutaneous hepatic perfusion in patients with liver cancer compared to best available care.
Project Status: Completed
Year Published: 2022
URL for additional information:
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Perfusion
  • Liver Neoplasms
  • Carcinoma, Hepatocellular
  • Chemotherapy, Cancer, Regional Perfusion
  • Antineoplastic Agents
  • Chemosaturation
  • liver cancer
  • percutaneous hepatic perfusion
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name:
Contact Email:
Copyright: HTA Austria - AIHTA GmbH
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.